Asociación entre la administración de vitamina C intravenosa y la recurrencia de manifestaciones clínicas producidas por infecciones respiratorias virales altas
No Thumbnail Available
Date
2025-01-10
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
Las infecciones respiratorias agudas afectan el aparato respiratorio por un lapso menor de 2 semanas, siendo las del tracto superior más frecuentes, autolimitadas y de etiología comúnmente viral. La vitamina C viene teniendo protagonismo por su efecto inmunomodulador en enfermedades inflamatorias y su potencial papel profiláctico en la recurrencia de manifestaciones virales altas en nuestro medio. Objetivo: Investigar la existencia de una asociación entre la administración de vitamina C intravenosa y la recurrencia de manifestaciones clínicas producidas por infecciones respiratorias virales altas (IRVA). Materiales y Métodos: Estudio cohorte prospectivo que reclutó 108 pacientes con tratamiento endovenoso de vitamina C durante 3 meses, por diagnósticos de artrosis, tendinitis y sinovitis, y 108 personas sin dicho tratamiento. Se evaluó la asociación mediante Chi cuadrado y se calculó el riesgo de recurrencia de una IRVA en ambos grupos mediante regresión de Poisson. Resultados: El 55.6% de pacientes no desarrollaron recurrencia de una IRVA tras la administración de vitamina C en contraste con el 13.9% que no recibió. El RR ajustado fue 0.53 (IC 95% 0.42 a 0.66). Conclusiones: El riesgo de manifestaciones clínicas por IRVA en aquellos con administración de vitamina C fue 47% menor respecto a aquellos sin dicha administración.
Palabras clave: Vitamina C intravenosa, Infecciones respiratorias virales altas, Manifestaciones Clínicas.
Abstract Acute respiratory infections affect the respiratory system for a period of less than 2 weeks, with upper respiratory tract infections being more frequent, self-limiting and commonly of viral etiology. Vitamin C has been gaining prominence due to its immunomodulatory effect in inflammatory diseases and its potential prophylactic role in the recurrence of upper viral manifestations in our setting. Objective: To investigate the existence of an association between the administration of intravenous vitamin C and the recurrence of clinical manifestations produced by upper respiratory viral infections (URVI). Materials and Methods: Prospective cohort study that recruited 108 patients with intravenous treatment with vitamin C for 3 months, for diagnoses of osteoarthritis, tendonitis and synovitis, and 108 people without such treatment. The association was evaluated using Chi-Square and the risk of recurrence of an URVI was calculated in both groups using Poisson’s regression. Results: The 55.6% of patients did not develop recurrence of UVRI after vitamin C administration compared with 13.9% who did not receive it. The adjusted RR was 0.53 (95% CI 0.42 to 0.66). Conclusions: The risk of clinical manifestations of UVRI in those receiving vitamin C was 47% lower than in those without it.
Abstract Acute respiratory infections affect the respiratory system for a period of less than 2 weeks, with upper respiratory tract infections being more frequent, self-limiting and commonly of viral etiology. Vitamin C has been gaining prominence due to its immunomodulatory effect in inflammatory diseases and its potential prophylactic role in the recurrence of upper viral manifestations in our setting. Objective: To investigate the existence of an association between the administration of intravenous vitamin C and the recurrence of clinical manifestations produced by upper respiratory viral infections (URVI). Materials and Methods: Prospective cohort study that recruited 108 patients with intravenous treatment with vitamin C for 3 months, for diagnoses of osteoarthritis, tendonitis and synovitis, and 108 people without such treatment. The association was evaluated using Chi-Square and the risk of recurrence of an URVI was calculated in both groups using Poisson’s regression. Results: The 55.6% of patients did not develop recurrence of UVRI after vitamin C administration compared with 13.9% who did not receive it. The adjusted RR was 0.53 (95% CI 0.42 to 0.66). Conclusions: The risk of clinical manifestations of UVRI in those receiving vitamin C was 47% lower than in those without it.
Description
Keywords
Vitamina C Intravenosa, Infecciones Respiratorias Virales Altas, Manifestaciones Clínicas